Immunohistochemical Expression of “L1 cell Adhesion Molecule†in Endometrial Carcinomas
DOI:
https://doi.org/10.3889/oamjms.2020.4633Keywords:
Endometrial carcinoma, L1 cell adhesion molecule, ImmunohistochemistryAbstract
BACKGROUND: Endometrial cancer is the most common cancer of the female genital tract. No effective biomarkers currently exist to allow for an efficient risk classification of endometrial carcinoma or to direct treatment (adjuvant radiation and/or chemotherapy) or to triage pelvic and para-aortic lymphadenectomy. L1 cell adhesion molecule (L1CAM) a transmembrane protein of the immunoglobulin family that has been implicated in promoting tumor cell proliferation, migration, invasion, and metastasis became an attractive candidate as a potential biomarker in endometrial carcinoma and potential therapeutic target in high-risk groups.
OBJECTIVES: Evaluation of L1CAM expression in endometrial carcinoma and correlation of this expression with various pathological parameters.
MATERIALS AND METHODS: Immunohistochemical staining for L1CAM was performed on paraffin-embedded sections of 80 cases of endometrial carcinomas that underwent total hysterectomy with bilateral salpingo-oophorectomy. Expression of L1CAM in >10% of tumor cells was interpreted as positive.
RESULTS: L1CAM expression was detected in 22.5% of cases and showed statistically significant correlation with non-endometrioid histological type, high grade, high FIGO stage, high pathological (T) stage, cervical involvement, nodal metastasis, lymphovascular space invasion, and high-risk tumor according to the European Society for Medical Oncology system for risk stratification (p < 0.05).
CONCLUSION: The high rate of L1CAM expression in high-risk endometrial carcinomas suggests that L1CAM represents a potential marker for the identification of patients needing closer follow-up and aggressive treatment. In addition, its potential role as a therapeutic target for high-risk endometrial cancer seems promising.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. PMid:30620402
Helal EA, Salman MI, Ezz-Elarab SS, editors. Malignant tumors of the body of uterus. In: Pathology Based Cancer Registry 2002-2010. Cairo, Egypt: Ain-Shams Faculty of Medicine; 2015. p. 54-6.
Mokhtar N, Salama A, Badawy O, Khorshed E, Mohamed G, Ibrahim M, et al, editors. Malignant tumors of female genital system. In: Pathology Cancer Registry 2000-2011. Cairo, Egypt: National Cancer Institute; 2016. p. 85-99.
Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094-108. https://doi.org/10.1016/s0140-6736(15)00130-0
Sanderson PA, Moulla A, Fegan KS. Endometrial cancer-an update. Obstet Gynaecol Reprod Med. 2019;29(8):225-32. https://doi.org/10.1016/j.ogrm.2019.05.001
Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: More than two types. Lancet Oncol. 2014;15(7):e268- 78. https://doi.org/10.1016/s1470-2045(13)70591-6
Kommoss F, Kommoss F, Grevenkamp F, Bunz AK, Taran FA, Fend F, et al. L1CAM: Amending the “low-risk†category in endometrial carcinoma. J Cancer Res Clin Oncol. 2017;143(2):255-62. https://doi.org/10.1007/ s00432-016-2276-3 PMid:27695947
Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, et al. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Modern Pathol. 2016;29(2):174-81. https:// doi.org/10.1038/modpathol.2015.147 PMid:26743472
Dellinger TH, Smith DD, Ouyang C, Warden CD, Williams JC, Han ES. L1CAM is an independent predictor of poor survival in endometrial cancer-an analysis of the cancer genome atlas (TCGA). Gynecol Oncol. 2016;141(2):336-40. https://doi. org/10.1016/j.ygyno.2016.02.003 PMid:26861585
Zaino R, Carinelli SG, Ellenson LH. Tumors of the uterine corpus. In: Kurman RJ, Carcagiu ML, Herrington CS, Young RH, editors. WHO Classification of Tumours of Female Reproductive Organs. Lyon, France: World Health Organization; 2014. p. 121-54.
Zhou Q, Singh SR, Yunzhe L, Mo Z, Huang J. Preoperative histopathological grading and clinical staging versus surgico-pathological grading and surgical staging in endometrial carcinoma patients: A single centre retrospective study. Glob J Med Res. 2018;18:18-28.
FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynecol Obstet. 2014;125(2):97-8. https://doi.org/10.1016/j. ijgo.2014.02.003 PMid:24630859
Powéll MA, Olawaiye AB, Bermudez A. Corpus uteri-carcinoma and carcinosarcoma. In: Amin MB, Edge SB, Greene FL, editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017. p. 639-57.
Colombo N, Creutzberg C, Amant F, Bosse T, González- MartÃn A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26(1):2-30. https://doi. org/10.1097/igc.0000000000000609 PMid:26645990
Klat J, Mladenka A, Dvorackova J, Bajsova S, Simetka O. L1CAM as a negative prognostic factor in endometrioid endometrial adenocarcinoma FIGO stage IA-IB. Anticancer Res. 2019;39(1):421-4. https://doi.org/10.21873/anticanres.13128 PMid:30591489
Corrado G, Laquintana V, Loria R, Carosi M, De Salvo L, Sperduti I, et al. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers. J Exp Clin Cancer Res. 2018;37(1):139. https://doi.org/10.1186/ s13046-018-0816-1 PMid:29980240
van der Putten LJ, Visser NC, Van de Vijver K, Santacana M, Bronsert P, Bulten J, et al. Added value of estrogen receptor, progesterone receptor, and L1 cell adhesion molecule expression to histology-based endometrial carcinoma recurrence prediction models: An ENITEC collaboration study. Int J Gynecol Cancer. 2018;28(3):514-23. https://doi. org/10.1097/igc.0000000000001187 PMid:29324536
Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, et al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018;119(4):480-6. https://doi.org/10.1038/s41416-018-0187-6 PMid:30050154
Pasanen A, Loukovaara M, Tuomi T, Bützow R. Preoperative risk stratification of endometrial carcinoma: L1CAM as a biomarker. Int J Gynecol Cancer. 2017;27(7):1318-24. https:// doi.org/10.1097/igc.0000000000001043 PMid:29059097
van der Putten LJ, Visser NC, Van de Vijver K, Santacana M, Bronsert P, Bulten J, et al. L1CAM expression in endometrial carcinomas: An ENITEC collaboration study. Br J Cancer. 2016;115(6):716-24. https://doi.org/10.1038/bjc.2016.235 PMid:27505134
Geels YP, Pijnenborg JM, Gordon BB, Fogel M, Altevogt P, Masadah R, et al. L1CAM expression is related to non-endometrioid histology, and prognostic for poor outcome in endometrioid endometrial carcinoma. Pathol Oncol Res. 2016;22(4):863-8. https://doi.org/10.1007/s12253-016-0047-8 PMid:26891628
Bosse T, Nout RA, Stelloo E, Dreef E, Nijman HW, Jürgenliemk- Schulz IM, et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results. Eur J Cancer. 2014;50(15):2602-10. https://doi.org/10.1016/j. ejca.2014.07.014 PMid:25126672
Tangen IL, Kopperud RK, Visser NC, Staff AC, Tingulstad S, Marcickiewicz J, et al. Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. Br J Cancer. 2017;117(6):840-7. https://doi. org/10.1038/bjc.2017.235 PMid:28751757
Visser NC, van der Putten LJ, van Egerschot A, Van de Vijver KK, Santacana M, Bronsert P, et al. Addition of IMP3 to L1CAM for discrimination between low-and high-grade endometrial carcinomas: A European network for individualised treatment of endometrial cancer collaboration study. Hum Pathol. 2019;89:90-8. https://doi.org/10.1016/j.humpath.2019.04.014 PMid:31054899
Weinberger V, Bednarikova M, Hausnerova J, Ovesna P, Vinklerova P, Minar L, et al. A novel approach to preoperative risk stratification in endometrial cancer: The added value of immunohistochemical markers. Front Oncol. 2019;9:265. https://doi.org/10.3389/fonc.2019.00265 PMid:31032226
Downloads
Published
How to Cite
License
Copyright (c) 2020 Aya Magdy Elyamany, Solafa Amin Abd-ElAziz, Samar A. Elsheikh, Somia A. M. Soliman (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
